These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 17667203)

  • 21. Trouble at the office.
    Allison M
    Nat Biotechnol; 2008 Sep; 26(9):967-9. PubMed ID: 18779797
    [No Abstract]   [Full Text] [Related]  

  • 22. Non-clinical Post-Marketing Commitments for newly licenced pharmaceuticals.
    Reeve LM
    Regul Toxicol Pharmacol; 2009 Nov; 55(2):181-7. PubMed ID: 19589365
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmaceutical postmarket review: fact or fiction?
    Schanz SJ
    Food Drug Law J; 2007; 62(3):493-500. PubMed ID: 17915391
    [No Abstract]   [Full Text] [Related]  

  • 24. Post-marketing strategies for medicines.
    Breckenridge A
    Clin Pharmacol Ther; 2008 Jan; 83(1):24-5; discussion 25. PubMed ID: 18043682
    [No Abstract]   [Full Text] [Related]  

  • 25. FDA asks LyphoMed to recall intravenous solution.
    Wagner M
    Mod Healthc; 1988 Jul; 18(31):5. PubMed ID: 10288204
    [No Abstract]   [Full Text] [Related]  

  • 26. Medical device reporting: issues with Class III medical devices.
    Zigler J; Walsh J; Zigler J
    Food Drug Law J; 2007; 62(3):573-80. PubMed ID: 17915398
    [No Abstract]   [Full Text] [Related]  

  • 27. Congress may force drug firms to reveal clinical trial data.
    Check E
    Nature; 2004 Sep; 431(7006):232. PubMed ID: 15371992
    [No Abstract]   [Full Text] [Related]  

  • 28. Current challenges with supply-chain integrity and the threat to the quality of marketed drugs.
    Paxton M
    Clin Pharmacol Ther; 2011 Feb; 89(2):316-9. PubMed ID: 21178987
    [No Abstract]   [Full Text] [Related]  

  • 29. An overview of FDA medical device regulation as it relates to deep brain stimulation devices.
    Peña C; Bowsher K; Costello A; De Luca R; Doll S; Li K; Schroeder M; Stevens T
    IEEE Trans Neural Syst Rehabil Eng; 2007 Sep; 15(3):421-4. PubMed ID: 17894274
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Timing of patent filing and market exclusivity.
    Dunn MK
    Nat Rev Drug Discov; 2011 Jul; 10(7):487-8. PubMed ID: 21720399
    [No Abstract]   [Full Text] [Related]  

  • 31. The FDA and the tort system: postmarketing surveillance, compensation, and the role of litigation.
    Struve CT
    Yale J Health Policy Law Ethics; 2005; 5(2):587-669. PubMed ID: 16052895
    [No Abstract]   [Full Text] [Related]  

  • 32. Drug regulation 2056.
    Bezold C; Peck J
    Food Drug Law J; 2005; 60(2):127-36. PubMed ID: 16097091
    [No Abstract]   [Full Text] [Related]  

  • 33. Round table: Post-marketing evaluation of fertility-regulating drugs as viewed by the pharmaceutical industry.
    Hum Reprod; 1987 Apr; 2(3):241-63. PubMed ID: 3597744
    [No Abstract]   [Full Text] [Related]  

  • 34. Commentary: can we talk? About Food and Drug Regulation and the First Amendment.
    Cohen MN
    Food Drug Law J; 2003; 58(4):741-56. PubMed ID: 15027458
    [No Abstract]   [Full Text] [Related]  

  • 35. FDA set to tighten guidelines on industry dissemination of information on unapproved uses of medical products.
    Lang L
    Gastroenterology; 2008 Apr; 134(4):905. PubMed ID: 18395067
    [No Abstract]   [Full Text] [Related]  

  • 36. Strategy for surveillance of adverse drug events.
    Bright RA
    Food Drug Law J; 2007; 62(3):605-16. PubMed ID: 17915403
    [No Abstract]   [Full Text] [Related]  

  • 37. Roadmap for revitalization?
    Nat Biotechnol; 2007 Oct; 25(10):1061. PubMed ID: 17921973
    [No Abstract]   [Full Text] [Related]  

  • 38. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Sep; 73(189):56487-91. PubMed ID: 18985960
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Sporicidin recall.
    Healthc Hazard Mater Manage; 1992 Jan; 5(4):9-11. PubMed ID: 10116667
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The need for a post-marketing surveillance program in Israel.
    Shemer J
    Isr Med Assoc J; 1999 Oct; 1(2):98-9. PubMed ID: 10731306
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.